Table 1 Baseline patient characteristics.
Characteristics | TEC (N = 210) |
|---|---|
Median age - yr (range) | 67 (33–91) |
≥75 yr, (%) | 49 (23.3) |
Gender, (%) | |
Female | 93 (44.3) |
Male | 117 (55.7) |
Race, no. (%) | |
White | 156 (74.3) |
Black | 19 (9.0) |
Asian | 19 (9.0) |
Other/unknown | 16 (7.6) |
Ethnicity - no. (%) | |
NonLatinX | 162 (77.1) |
LatinX | 23 (11.0) |
Unknown | 25 (11.9) |
ECOG Performance Status—no./total no. (%) | |
0 | 21/130 (16.2) |
1 | 74/130 (56.9) |
2 | 24/130 (18.5) |
3 | 11/130 (8.5) |
Stage (ISS) - no./total no. (%) | |
I | 47/124 (37.9) |
II | 39/124 (31.5) |
III | 38/124 (30.6) |
Isotype MM – no./total no. (%) | |
IgG | 99/204 (48.5) |
IgA | 50/204 (24.5) |
Light chain only | 51/204 (25.0) |
Other | 4/204 (2.0) |
Cytogenetic risk category – no./total no. (%) | |
Standard-risk | 82/164 (50.0) |
High riska | 82/164 (50.0) |
Missing | 46 |
Presence of EMDb – no./total no. (%) | 37/126 (29.4) |
CrCl <30 ml/min – no./total no. (%) | 26/209 (12.4) |
Time from diagnosis to first TEC dose (range), yr | 6.1 (0.6-29.2) |
Median prior lines of therapy (range) | 6 (1–20) |
Refractory status—no./total no. (%) | |
Triple-class refractoryc | 138/167 (82.6) |
Penta-drug refractoryd | 71/161 (44.1) |
Prior BCMA exposure – no./total no. (%) | 92/210 (43.8) |
CAR T alone | 42/92 (45.7) |
ADC alone | 27/92 (29.3) |
BsAb alone | 6/92 (6.5) |
ADC + BCMA CAR T | 16/92 (17.4) |
ADC + BCMA CAR T + bsAb | 1/92 (1.1) |
Prior GPRC5D exposure – no./total no. (%) | 9/197 (4.6) |
Received > 1 BCMA, GPRC5D, and/or other T-cell engaging therapies – no. (%) | 27 (12.9) |
MajesTEC-1 ineligible – no./total no. (%) | 149/199 (71.0) |
